Recommended starting dose adjustments for patients with renal impairment.
Capsules shown are not actual size.
Dose modification is recommended to manage Grade 3 or 4 hematologic events thought to be related to therapy with REVLIMID.1
For non-hematologic Grade 3 or 4 toxicities judged to be related to REVLIMID, hold treatment and restart treatment at the next lower dose level when toxicity has resolved to ≤Grade 2 at the physician’s discretion.
Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions.